WINT.OQ
Latest Trade
3.67USDChange
-0.35(-8.71%)Volume
14,808Today's Range
-
4.0652 Week Range
-
10.03As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 4.02 |
---|---|
Open | 4.03 |
Volume | 14,808 |
3M AVG Volume | 0.96 |
Today's High | 4.06 |
Today's Low | 3.60 |
52 Week High | 10.03 |
52 Week Low | 3.60 |
Shares Out (MIL) | 16.92 |
Market Cap (MIL) | 62.10 |
Forward P/E | -1.75 |
Dividend (Yield %) | -- |
Windtree Therapeutics Reports Q3 Loss Per Share $0.54
Windtree Says FDA Acceptance Of Ind Application For A Phase 2 Clinical Trial Studying Kl4 Surfactant In Acute Lung Injury In Adults With Covid-19
Windtree Therapeutics Files For Mixed Shelf Of Upto $75 Mln - SEC Filing
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company's technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company's core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.
Industry
Biotechnology & Drugs
Contact Info
2600 Kelly Rd Ste 100
WARRINGTON, PA
18976-3652
United States
+1.215.4889300
http://www.windtreetx.com/Executive Leadership
James Z. Huang
Independent Chairman of the Board
Craig E. Fraser
President, Chief Executive Officer, Director
John P. Hamill
Chief Financial Officer, Senior Vice President
Eric L. Curtis
Chief Operating Officer, Senior Vice President
Joseph Soffer
Executive Vice President - Clinical Development
Price To Earnings (TTM) | -- |
---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 0.82 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 23.86 |
LT Debt To Equity (MRQ) | 22.93 |
Return on Investment (TTM) | -33.05 |
Return on Equity (TTM) | -29.65 |
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.